Loading
Palacaparib is an experimental DNA-repair inhibitor designed to reach the brain and selectively block PARP1.
The primary discovery publication identifies AZD9574/palacaparib as a brain-penetrant PARP1-selective inhibitor. CERTIS1 (NCT05417594) is recruiting with 695 planned participants and was updated in October 2026. It studies monotherapy and combinations including temozolomide, trastuzumab deruxtecan and datopotamab deruxtecan. A registry-wide recruiting state does not confirm a specific local site or available slot. Brain exposure and PARP1 selectivity are development features; human superiority, marrow sparing and a breast-cancer indication are not established.
PARP1-selective, brain-penetrant inhibitor and trapper (AZD9574). Connects to PARP.
1.Palacaparib slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Palacaparib" OR ABSTRACT:"Palacaparib" OR TITLE:"AZD9574" OR ABSTRACT:"AZD9574") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Palacaparib, not a curated reading list.
Shares Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors, AstraZeneca, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors, A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies, PARP, Endometrial cancer and the tag pipeline.
Shares Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer, AstraZeneca and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares PARP, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/